
Oncology NEWS International
- Oncology NEWS International Vol 16 No 6
- Volume 16
- Issue 6
Enrollment Begins for Phase I Trial of NPI-0052 in Myeloma
NORWALK, Connecticut—The Multiple Myeloma Research Consortium (MMRC) and Nereus Pharmaceuticals, Inc., San Diego, have initiated enrollment in a multicenter phase I clinical trial to study Nereus' novel, second-generation proteasome inhibitor NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma. Participants in the open-label study will receive escalating, once-weekly intravenous doses of NPI-0052. The compound was discovered during the fermentation of a new marine actinomycete (Salinispora tropica).
NORWALK, ConnecticutThe Multiple Myeloma Research Consortium (MMRC) and Nereus Pharmaceuticals, Inc., San Diego, have initiated enrollment in a multicenter phase I clinical trial to study Nereus' novel, second-generation proteasome inhibitor NPI-0052 in patients with relapsed or relapsed/refractory multiple myeloma. Participants in the open-label study will receive escalating, once-weekly intravenous doses of NPI-0052. The compound was discovered during the fermentation of a new marine actinomycete (Salinispora tropica).
Articles in this issue
almost 19 years ago
ACS Launches Major Epidemiology Studyalmost 19 years ago
Pt Selection Key to Radioembolization of Liver Ca'salmost 19 years ago
Million Dollar Gotham Prize Announcedalmost 19 years ago
Diagnostic Dilemma: GI Diseasealmost 19 years ago
Velcade/Doxil Approved for Relapsed or Refractory Multiple Myeloma Ptsalmost 19 years ago
Junovan Fails to Win ODAC Nod for Osteosarcoma Treatmentalmost 19 years ago
Surveillance Colonoscopy Guidelines Not Being Followedalmost 19 years ago
Removing Stage IV Primary May Cut Mortalityalmost 19 years ago
Nuclear Export Inhibitors Testing Moving Forwardalmost 19 years ago
ODAC: orBec Yields No 'Substantial Efficacy' in GI GVHDNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.























































